Key facts
- It has raised $360K; the latest was Early Stage VC ($360K) in Jan 2025.
- Notable investors include Innovatiefonds Noord-Holland, ScaleNL.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for VirXcel
- ·The full record, as it builds
Funding rounds
No funding rounds for VirXcel are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About VirXcel
Operator of a healthcare company intended to develop innovative strategies to prevent and mitigate respiratory viral infections. The company specializes in developing macrocyclic peptides as antiviral agents distinguished by their compact size, significantly smaller than that of antibodies to unlock their full potential against respiratory and emerging viral threats, enabling hospitals to provide targeted therapies.
- Sector
- Healthcare
- HQ
- Amsterdam, Netherlands
- Founded
- 2024
- Employees
- 2
- Website
- virxcel.com/
- Ownership
- Privately Held (backing)
VirXcel doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in VirXcel shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on VirXcel in its N-PORT filings yet. We sweep new filings monthly.